Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 2/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.41 |
| ▸ | PRCP | P42785 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | EPHX1 | P07099 | 3/20 | 0.38 |
| ▸ | HTR1A | P08908 | 3/20 | 0.38 |
| ▸ | HTR2A | P28223 | 3/20 | 0.38 |
| ▸ | DRD3 | P35462 | 3/20 | 0.38 |
| ▸ | HTR2C | P28335 | 2/20 | 0.38 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.38 |
| ▸ | DRD2 | P14416 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7042289 | 0.85 | NPC1 (0.45) | THRBHDAC8PRCPLMNASMN1; SMN2 | |
| SCHEMBL7664595 | 0.85 | NPC1 (0.45) | THRBHDAC8PRCPLMNASMN1; SMN2 | |
| SCHEMBL7042291 | 0.85 | NPC1 (0.45) | THRBHDAC8PRCPLMNASMN1; SMN2 | |
| SCHEMBL7041535 | 0.83 | HDAC8 (0.48) | ALDH1A1HDAC8LMNASMN1; SMN2GAA | |
| SCHEMBL7042773 | 0.83 | HDAC8 (0.48) | ALDH1A1HDAC8LMNASMN1; SMN2GAA | |
| SCHEMBL7668937 | 0.83 | HDAC8 (0.48) | ALDH1A1HDAC8LMNASMN1; SMN2GAA | |
| SCHEMBL7044762 | 0.82 | MAPT (0.54) | ALDH1A1PRCPGAAHTR1AHTR2A | |
| SCHEMBL7039228 | 0.77 | L3MBTL1 (0.51) | HDAC8LMNASMN1; SMN2HTR2C | |
| SCHEMBL13889887 | 0.76 | GAA (0.42) | ALDH1A1HDAC8GAA | |
| SCHEMBL3256076 | 0.75 | PDE5A (0.41) | ALDH1A1SMN1; SMN2GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030027743-A1 | Tripeptidylpeptidase inhibitors | INSERM | 2003-02-06 | — | — | US | disclosed |
| US-6403561-B1 | DISORDERS ASSOCIATED WITH THE INACTIVATION OR EXCESSIVE DEGRADATION OF CHOLECYSTOKININ; INHIBITING THE ENZYMATIC HYDROLYSIS OF CHOLECYSTOKININ 1-(2(S)-AMINOBUTYRYL)-2(S)-INDOLINECARBOXYLIC ACID | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2002-06-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030027743-A1 | Tripeptidylpeptidase inhibitors | DPP4, DPP3, DPP9 | ALOX15 2996/4885ALDH1A1 630/4885ALOX12 3692/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.